237 related articles for article (PubMed ID: 36709039)
1. Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.
Bayle A; Belcaid L; Aldea M; Vasseur D; Peyraud F; Nicotra C; Geraud A; Sakkal M; Seknazi L; Cerbone L; Blanc-Durand F; Hadoux J; Mosele F; Tagliamento M; Bernard-Tessier A; Verret B; Smolenschi C; Clodion R; Auger N; Romano PM; Gazzah A; Camus MN; Micol J; Caron O; Hollebecque A; Loriot Y; Besse B; Lacroix L; Rouleau E; Ponce S; Soria JC; Barlesi F; Andre F; Italiano A
Ann Oncol; 2023 Apr; 34(4):389-396. PubMed ID: 36709039
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer.
Helal C; Pobel C; Bayle A; Vasseur D; Nicotra C; Blanc-Durand F; Naoun N; Bernard-Tessier A; Patrikidou A; Colomba E; Flippot R; Fuerea A; Auger N; Ngo Camus M; Besse B; Lacroix L; Rouleau E; Ponce S; Italiano A; Loriot Y
Eur J Cancer; 2023 Dec; 195():113368. PubMed ID: 37897866
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.
Zugazagoitia J; Ramos I; Trigo JM; Palka M; Gómez-Rueda A; Jantus-Lewintre E; Camps C; Isla D; Iranzo P; Ponce-Aix S; García-Campelo R; Provencio M; Franco F; Bernabé R; Juan-Vidal O; Felip E; de Castro J; Sanchez-Torres JM; Faul I; Lanman RB; Garrido P; Paz-Ares L
Ann Oncol; 2019 Feb; 30(2):290-296. PubMed ID: 30535340
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
5. Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG; Gyanchandani R; Shah OS; Gurda GT; Lucas PC; Hartmaier RJ; Brufsky AM; Puhalla S; Bahreini A; Kota K; Wald AI; Nikiforov YE; Nikiforova MN; Oesterreich S; Lee AV
Breast Cancer Res; 2019 Feb; 21(1):22. PubMed ID: 30736836
[TBL] [Abstract][Full Text] [Related]
6. The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.
Giacomini P; Valenti F; Allegretti M; Pallocca M; De Nicola F; Ciuffreda L; Fanciulli M; Scalera S; Buglioni S; Melucci E; Casini B; Carosi M; Pescarmona E; Giordani E; Sperati F; Jannitti N; Betti M; Maugeri-Saccà M; Cecere FL; Villani V; Pace A; Appetecchia M; Vici P; Savarese A; Krasniqi E; Ferraresi V; Russillo M; Fabi A; Landi L; Minuti G; Cappuzzo F; Zeuli M; Ciliberto G
J Transl Med; 2023 Oct; 21(1):725. PubMed ID: 37845764
[TBL] [Abstract][Full Text] [Related]
7. A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.
George SL; Izquierdo E; Campbell J; Koutroumanidou E; Proszek P; Jamal S; Hughes D; Yuan L; Marshall LV; Carceller F; Chisholm JC; Vaidya S; Mandeville H; Angelini P; Wasti A; Bexelius T; Thway K; Gatz SA; Clarke M; Al-Lazikani B; Barone G; Anderson J; Tweddle DA; Gonzalez D; Walker BA; Barton J; Depani S; Eze J; Ahmed SW; Moreno L; Pearson A; Shipley J; Jones C; Hargrave D; Jacques TS; Hubank M; Chesler L
Eur J Cancer; 2019 Nov; 121():224-235. PubMed ID: 31543384
[TBL] [Abstract][Full Text] [Related]
8. Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
Takeda M; Takahama T; Sakai K; Shimizu S; Watanabe S; Kawakami H; Tanaka K; Sato C; Hayashi H; Nonagase Y; Yonesaka K; Takegawa N; Okuno T; Yoshida T; Fumita S; Suzuki S; Haratani K; Saigoh K; Ito A; Mitsudomi T; Handa H; Fukuoka K; Nakagawa K; Nishio K
Oncologist; 2021 Apr; 26(4):e588-e596. PubMed ID: 33325566
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
[TBL] [Abstract][Full Text] [Related]
10. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
11. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses.
Huang CC; Tsai YF; Liu CY; Chao TC; Lien PJ; Lin YS; Feng CJ; Chiu JH; Hsu CY; Tseng LM
BMC Cancer; 2021 Feb; 21(1):199. PubMed ID: 33632156
[TBL] [Abstract][Full Text] [Related]
13. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
[TBL] [Abstract][Full Text] [Related]
14. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
[TBL] [Abstract][Full Text] [Related]
15. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
[TBL] [Abstract][Full Text] [Related]
16. Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis.
Padovan M; Maccari M; Bosio A; De Toni C; Vizzaccaro S; Cestonaro I; Corrà M; Caccese M; Cerretti G; Zagonel V; Lombardi G
Eur J Cancer; 2023 Sep; 191():112959. PubMed ID: 37481865
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
[TBL] [Abstract][Full Text] [Related]
18. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
[TBL] [Abstract][Full Text] [Related]
19. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing.
Schwaederle M; Chattopadhyay R; Kato S; Fanta PT; Banks KC; Choi IS; Piccioni DE; Ikeda S; Talasaz A; Lanman RB; Bazhenova L; Kurzrock R
Cancer Res; 2017 Oct; 77(19):5419-5427. PubMed ID: 28807936
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study.
Bayle A; Belcaid L; Palmieri LJ; Teysonneau D; Cousin S; Spalato-Ceruso M; Aldea M; Vasseur D; Alame M; Blouin L; Soubeyran I; Nicotra C; Ngocamus M; Hollebecque A; Loriot Y; Besse B; Lacroix L; Rouleau E; Barlesi F; Andre F; Italiano A
Mol Cancer; 2023 Nov; 22(1):176. PubMed ID: 37924050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
